Cargando…
Benefits and limitations of serological assays in COVID-19 infection
Accurate and rapid diagnostic tests are critical for achieving control of coronavirus disease 2019 (covid-19), a pandemic illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Diagnostic tests for covid-19 fall into two main categories: molecular tests that detect viral RNA...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tuberculosis Association of India. Published by Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409828/ https://www.ncbi.nlm.nih.gov/pubmed/33308664 http://dx.doi.org/10.1016/j.ijtb.2020.07.034 |
_version_ | 1783568132505337856 |
---|---|
author | Sidiq, Zeeshan Hanif, M. Dwivedi, Kaushal Kumar Chopra, K.K. |
author_facet | Sidiq, Zeeshan Hanif, M. Dwivedi, Kaushal Kumar Chopra, K.K. |
author_sort | Sidiq, Zeeshan |
collection | PubMed |
description | Accurate and rapid diagnostic tests are critical for achieving control of coronavirus disease 2019 (covid-19), a pandemic illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Diagnostic tests for covid-19 fall into two main categories: molecular tests that detect viral RNA, and serological tests that detect anti-SARS-CoV-2 immunoglobulins. Reverse transcriptase polymerase chain reaction (RT-PCR), a molecular test, has become the gold standard for diagnosis of covid-19; however, this test has many limitations that include potential false negative results, changes in diagnostic accuracy over the disease course, and precarious availability of test materials. Serological tests have generated substantial interest as an alternative or complement to RT-PCR and other Nucleic acid tests in the diagnosis of acute infection, as some might be cheaper and easier to implement at the point of care. A clear advantage of these tests over RT-PCR is that they can identify individuals previously infected by SARS-CoV-2, even if they never underwent testing while acutely ill. Many serological tests for covid-19 have become available in a short period, including some marketed for use as rapid, point-of-care tests. The pace of development has, however, exceeded that of rigorous evaluation, and important uncertainty about test accuracy remains. |
format | Online Article Text |
id | pubmed-7409828 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Tuberculosis Association of India. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74098282020-08-07 Benefits and limitations of serological assays in COVID-19 infection Sidiq, Zeeshan Hanif, M. Dwivedi, Kaushal Kumar Chopra, K.K. Indian J Tuberc Review Article Accurate and rapid diagnostic tests are critical for achieving control of coronavirus disease 2019 (covid-19), a pandemic illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Diagnostic tests for covid-19 fall into two main categories: molecular tests that detect viral RNA, and serological tests that detect anti-SARS-CoV-2 immunoglobulins. Reverse transcriptase polymerase chain reaction (RT-PCR), a molecular test, has become the gold standard for diagnosis of covid-19; however, this test has many limitations that include potential false negative results, changes in diagnostic accuracy over the disease course, and precarious availability of test materials. Serological tests have generated substantial interest as an alternative or complement to RT-PCR and other Nucleic acid tests in the diagnosis of acute infection, as some might be cheaper and easier to implement at the point of care. A clear advantage of these tests over RT-PCR is that they can identify individuals previously infected by SARS-CoV-2, even if they never underwent testing while acutely ill. Many serological tests for covid-19 have become available in a short period, including some marketed for use as rapid, point-of-care tests. The pace of development has, however, exceeded that of rigorous evaluation, and important uncertainty about test accuracy remains. Tuberculosis Association of India. Published by Elsevier B.V. 2020-12 2020-08-06 /pmc/articles/PMC7409828/ /pubmed/33308664 http://dx.doi.org/10.1016/j.ijtb.2020.07.034 Text en © 2020 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Article Sidiq, Zeeshan Hanif, M. Dwivedi, Kaushal Kumar Chopra, K.K. Benefits and limitations of serological assays in COVID-19 infection |
title | Benefits and limitations of serological assays in COVID-19 infection |
title_full | Benefits and limitations of serological assays in COVID-19 infection |
title_fullStr | Benefits and limitations of serological assays in COVID-19 infection |
title_full_unstemmed | Benefits and limitations of serological assays in COVID-19 infection |
title_short | Benefits and limitations of serological assays in COVID-19 infection |
title_sort | benefits and limitations of serological assays in covid-19 infection |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409828/ https://www.ncbi.nlm.nih.gov/pubmed/33308664 http://dx.doi.org/10.1016/j.ijtb.2020.07.034 |
work_keys_str_mv | AT sidiqzeeshan benefitsandlimitationsofserologicalassaysincovid19infection AT hanifm benefitsandlimitationsofserologicalassaysincovid19infection AT dwivedikaushalkumar benefitsandlimitationsofserologicalassaysincovid19infection AT choprakk benefitsandlimitationsofserologicalassaysincovid19infection |